In this regard, we have assessed the efficacy of transferrin receptor (TrfR)-targeted SNALPs encapsulating gene-silencing tools for chronic myeloid leukemia (CML) treatment [139]. This evidence concerns the gene TFRC and chronic myelogenous leukemia, BCR-ABL1 positive.